FDA drug class
Programmed Death Receptor-1 Blocking Antibodies list
Every FDA-approved prescription drug the FDA NDC directory tags with the Programmed Death Receptor-1 Blocking Antibody [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 7 single-ingredient drugs in this class: atezolizumab, dostarlimab, nivolumab, pembrolizumab, retifanlimab, tislelizumab, toripalimab. Another 4 combination products include one of them.
Run it in Rivvi
Map Tecentriq and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Programmed Death Receptor-1 Blocking Antibodies (11)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | Single ingredient | 2 | Not controlled |
| Dostarlimab | Jemperli | Single ingredient | 1 | Not controlled |
| Nivolumab | Opdivo | Single ingredient | 4 | Not controlled |
| Pembrolizumab | Keytruda | Single ingredient | 1 | Not controlled |
| Retifanlimab | Zynyz | Single ingredient | 1 | Not controlled |
| Tislelizumab | Tevimbra | Single ingredient | 2 | Not controlled |
| Toripalimab | Loqtorzi | Single ingredient | 1 | Not controlled |
| Atezolizumab and hyaluronidase (human recombinant) | Tecentriq Hybreza | Combination | 1 | Not controlled |
| Nivolumab and hyaluronidase (human recombinant) | Opdivo Qvantig | Combination | 2 | Not controlled |
| Nivolumab and relatlimab | Opdualag | Combination | 1 | Not controlled |
| Pembrolizumab and berahyaluronidase alfa | Keytruda Qlex | Combination | 2 | Not controlled |
FDA established pharmacologic class: Programmed Death Receptor-1 Blocking Antibody [EPC].
Questions
What drugs are Programmed Death Receptor-1 Blocking Antibodies?
The FDA NDC directory lists 7 single-ingredient drugs in this class: atezolizumab, dostarlimab, nivolumab, pembrolizumab, retifanlimab, tislelizumab, toripalimab. Another 4 combination products include one of them.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.